Other Actions across the Health Theme:
Support for increased participation of SMEs:
- SME go Health supports the successful participation of research centers, universities and innovative SMEs in EU-funded "HEALTH" research projects. It helps them to find project partners, build or participate in European R&D projects in the EU-funded "Health" thematic priority of FP7.
"SMEs go Health" is an initiative of the EU Commission supported by a network of experts and National Contact Points in 30 countries.
- This activity is complemented by the project SM Bio Power, focussing on SMEs in medical technologies and biomedical engineering, encouraging them to participate in EU research. An online helpdesk is available for registered users as is personal assistance in identifying funding opportunities and project partners.
Both projects work in synergy to support high-tech, research intensive SMEs in Health Research to participate in FP7 Health proposals.
- The French company Genewave coordinated two EU funded projects, composed of complementary SMEs and Academics. The FP6 Quantitative Analysis of Genes in Single Cells (QUAGSIC) has been very successfully completed with the development of a prototype. The just started FP7 Portable and automated test for fast detection and surveillance of Influenza (PORTFASTFLU), aims to develop a rapid screening system that will revolutionise control of influenza epidemics.
PORTFASTFLU aims to develop and validate a rapid diagnostic system for influenza that will be used for surveillance and early detection of influenza, and as a point-of-care tool in developed and developing countries.
Support for SMEs results valorisation:
The three-year project aiming at ‘Key Performance Factor Assessment and Valorisation for Successful EU-FP Project Participation of Innovative SMEs in the Area of HEALTH’ will accelerate and enhance the dissemination and exploitation of project outcomes, ultimately providing a published ‘Decalogue’ of golden rules for the success of innovative SMEs.
The project involves 7 partners from the following 6 countries:
Belgium, Germany, Switzerland, Israel, France and Greece.
EC contribution: €750 000
The four-year project ‘Relating Expectations and Needs to Participation and Empowerment of Children in Clinical Trials’ will aim primarily to clarify the expectations and needs of children who have participated or who might participate in clinical trials for new drugs in Europe and their families. It also seeks to identify methods by which those expectations and needs can be translated to empower and motivate participants of future clinical trials. Greater participation in clinical trials will result in more valid and reliable products available for children as
envisaged by the Paediatric Regulation EC 1901/2006.
The project involves 7 partners from the following 5 countries:
Sweden, Germany, Belgium, Slovenia and Italy.
EC contribution: €500 000
The 12-month project ‘Enhancing Public Awareness on the Results of European Health Research Actions through Television Media’ will exploit and customise a highly innovative TV media communication model. The project expects to have each of its audiovisual productions broadcast by at least eight major national TV stations throughout Europe and to reach an overall public audience of several millions of people.
The project involves 4 partners from the following 3 countries:
Italy, France and Germany.
EC contribution: €700 000
Responding to EU policy needs:
The three-year project ‘Evaluation of Legislation and Related Guidelines on the Procurement, Storage and Transfer of Human Tissues and Cells in the European
Union: an Evidence-Based Impact Analysis’ will analyse the impact of current EU legislation and guidelines on biomedical research and will identify regulation deficits and inconsistencies.
The project involves 10 partners from the following 9 countries:
Germany, United Kingdom, Sweden, Hungary, Italy, Ireland, France, the Netherlands and Lithuania.
EC contribution: €798 000
Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium (link to table below). The three-year project ‘Development of Six Mercaptopurine and Methotrexate Oral Liquid Formulations for the Maintenance Treatment of Acute Lymphoblastic Leukaemia in Children’ will perform nonclinical and clinical development with the crucial objective of making its adapted formulations available by 2010 at the latest.
This Consortium is composed of highly qualified organizations and notorious clinicians in paediatric hemato-oncology. It is an integrated team of competencies (clinicians, pædiatricians, pharmacokineticists, pharmacists, manufacturers, engineers, regulatory and ethical experts) capable of executing a pædiatric drug development from its designing to market.
The project involves 7 partners from the following 4 countries:
France, Denmark, the Netherlands and United Kingdom.
EC contribution: €3.3 million
|1||Only for Children Pharmaceuticals||France
|2||ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS||France
|3||COPENHAGEN UNIVERSITY HOSPITAL||Denmark
|4||Laboratoire Philippe DAVIOUD SAS||France
|6||France Europe Innovation||France
|9||HOSPICES CIVILS DE LYON||France
|10||CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL||Germany
The three-year project ‘An Inquiry into Health and Safety at Work: A European Union Perspective’ aims to review current knowledge and issues related to the economic impact of health at work. It will carry out a comparative EU-wide assessment of the structure and dynamics of health and safety at work. Policy recommendations aiming to improve health and safety at work, in the context of a changing labour-market environment, shall be detailed with particular reference to the ageing population, the feminisation of the labour markets and the increase in small and medium -sized enterprises (SMEs).
The project involves 19 partners from the following 13 countries:
United Kingdom, France, Lithuania, Denmark, Greece, Belgium, Finland, Germany, Spain, the Netherlands, Poland, Hungary and Italy.
EC contribution: €1.1 million
The project ‘Health system analysis to support capacity development to respond
to pandemic infl uenza in Asia’ (AsiaFluCap) will last three years and use
operational planning in order to implement strategic pandemic infl uenza plans.
It will provide a framework for evaluating the operational capacity of health systems
in Vietnam, Indonesia, Thailand and Taiwan. The project will systematically
identify gaps in the operational capacity of the different countries in order to best
support the containment and mitigation of pandemic infl uenza.
The project involves 12 partners from 9 countries:
United Kingdom, Thailand, Germany, the Netherlands, Taiwan, Cambodia, Indonesia, Lao PDR and Vietnam
‘Organocatalytic approaches towards easily synthesised, economical and
high-yielding Oseltamivir derivatives’ (CATAFLU.OR) is a three-year project
that addresses a new ‘domino’ reaction based on an organocatalytic approach
to the synthesis of new Oseltamivir derivatives.
Neuraminidase is an essential enzyme for viral replication in infl uenza viruses.
Inhibitors of neuraminidase such as oseltamivir phosphate (Tamifl u®) or
zanamivir (Relenza®) are essential for defence against infl uenza and for the
possible mitigation of a pandemic. Public demand for the stockpiling of Oseltamivir
derivatives has greatly increased recently. However, natural sources of
the drug are scarce and the ways known for synthesizing it are complex and
expensive. Therefore, new pathways are required for chemical synthesis, in
order to identify new drug candidates, cut the costs and improve upon availability
and effi ciency.
The project involves 7 partners from 5 countries:
Italy, Slovakia, Germany, Finland and China
International Mouse Knockout Consortium (IMKC)
Genome Canada, the European Commission, and the National Institutes
of Health (NIH) from within the US Department of Health and Human
Services (HHS) agreed to a collaborative effort to functionally annotate
the genome, using the powerful tools of mouse genetics. This
mouse-gene knockout resource has now been accelerated through
three large-scale programmes: The North American Conditional Mouse
Mutagenesis Project (NORCOMM), The European Conditional Mouse
Mutagenesis Project (EUCOMM fi nanced by the European Commission)
and the US Knockout Mouse Project (KOMP).
KOMP, EUCOMM, and NorCOMM have agreed to share gene lists and
data to help coordinate these international efforts. Development of the
vectors, mutant embryonic stem (ES) cells, mice and distribution networks
for producing a knockout mutation for every gene in the mouse
genome will provide valuable research tools in the short-term. It will reduce
overall costs to the research community by shortening the time
needed to produce experimental data. It will also provide a base for
future research in a wide range of areas for many years to come.
The five-year project ‘Supporting the Use of Research Evidence for Policy in African Health Systems’ seeks to improve access to and use of policy-relevant syntheses of research evidence that are contextualised and tailored to meet the needs of decision makers in low- and middle-income countries. SURE will develop capacity for evidence-informed health care policy and undertake a comparative evaluation of initiatives between policy makers, researchers, and civil society using a range of different strategies.
The project involves 12 partners from the following 11 countries:
Norway, France, Sweden, Canada, Burkina Faso, Cameroon, Central African Republic, Ethiopia, Mozambique, Uganda and Zambia as well as the World Health Organization.
EC contribution: €3 million